Similarly, etranacogene dezaparvovec represents a promising innovation for hemophilia B, offering a cost-effective alternative to lifelong coagulation factor IX therapy, though the evidence remains limited due to its recent approval. This evidence concerns the gene F9 and hemophilia B.